Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | LTK | P29376 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383145 | 0.86 | GRIN2D (0.56) | POLBAURKADAPK3JAK2PRKD3 | |
| SCHEMBL30973144 | 0.86 | GRIN2D (0.56) | POLBAURKADAPK3JAK2PRKD3 | |
| SCHEMBL3267868 | 0.82 | MAPT (0.50) | POLBPTK6GAALMNAKDM4E | |
| SCHEMBL2730824 | 0.79 | METAP2 (0.60) | POLBAURKADAPK3JAK2PRKD3 | |
| SCHEMBL182445 | 0.79 | JAK2 (0.60) | AURKADAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL30013301 | 0.79 | METAP2 (0.60) | POLBAURKADAPK3JAK2PRKD3 | |
| SCHEMBL29874884 | 0.76 | ALDH1A1 (0.56) | POLBPKMLMNAKDM4EMAPT | |
| SCHEMBL16208357 | 0.76 | ALDH1A1 (0.56) | POLBPKMLMNAKDM4EMAPT | |
| SCHEMBL24576225 | 0.76 | LMNA (0.50) | AURKADAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL22425073 | 0.73 | MAPT (0.66) | POLBGAALMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12378463-B2 | Water-based resin with elasticity for applications in cementing and subterranean structures | SAUDI ARABIAN OIL COMPANY (SA) | 2025-08-05 | — | — | US | disclosed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| CN-116102541-B | Compounds as NMT inhibitors and uses thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-1221443-B1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-6699880-B1 | STIMULATE MUSCARINIC ACETYLCHOLINE RECEPTORS M4, ANALGESICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | LIGAND PHARMACEUTICALS INCORPORATED | 2002-10-17 | — | — | US | disclosed |
| US-20020115853-A1 | Benzimidazolones and analogues | WYETH | 2002-08-22 | — | — | US | disclosed |
| US-6423699-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| EP-1221443-A1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-6380235-B1 | USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | POLB 3514/4885PTK6 3744/4885IDO1 460/4885 |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | POLB 1284/4885PTK6 1538/4885IDO1 3112/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | POLB 978/4885PTK6 693/4885IDO1 1385/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | POLB 2355/4885PTK6 2368/4885IDO1 4135/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | POLB 4583/4885PTK6 1159/4885IDO1 982/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | POLB 4205/4885PTK6 940/4885IDO1 1989/4885 |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | PGR, GNRHR, NR4A1 | POLB 4460/4885PTK6 1169/4885IDO1 957/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | POLB 2516/4885PTK6 3889/4885IDO1 769/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | POLB 1498/4885PTK6 539/4885IDO1 3549/4885 |
| US-20020115853-A1 | Benzimidazolones and analogues | PGR, NR5A1, NR3C2 | POLB 3940/4885PTK6 939/4885IDO1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.